DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global ...

Long COVID, a debilitating condition following SARS-CoV-2 infection, continues to disable tens of millions of people globally ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...

Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S(Nasdaq: GMAB) announced today that it has filed its Annual Report ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...